-
-
In this issue: ACEI/ARB therapy for AS; safety alert issued for dronedarone; statins and cancer risk; nesiritide and heart failure; and FDA actions.
-
The association of HPV infection and bladder cancer has been a topic of discussion for the last decade, but has not surfaced because of important other outcomes of HPV infection. HPV is increasing in its prevalence globally and its chronic nature raises many issues in and around the genital tract.
-
Herrera and colleagues reviewed the use of interferon-ã release assays (IGRAs) for the diagnosis of latent tuberculosis infection (LTBI).
-
A total of 1,763 HIV-1 serodiscordant couples in nine countries with the infected partner having CD4+ counts of 350-500/mL were randomized 1:1 to early (immediate) vs. delayed (CD4+ had declined to ¡Ü 250/mL or after development of an AIDS-related illness) antiretroviral therapy of the infected partner.
-
Clostridium difficile infection (CDI) is a serious medical condition associated with significant morbidity and mortality. Thirty-day mortality rates associated with CDI have been estimated to be anywhere from 6.0% to 32.5%, with higher mortality rates observed in older patients.
-
Unless you were bent on becoming a forensic entomologist as a kid, there is nothing worse than pulling back a bed sheet and finding ... maggots. Every so many years, I find an ICU patient, typically sedated and intubated, with fly larvae crawling out of some orifice or wound.
-
It took polymerase chain reaction at least 30 years (by my reckoning) to evolve from its inception as a promising method for laboratory detection of infectious agents in patient samples to its widespread utilization in diagnostic clinical microbiology laboratories.
-
When a single imported case of measles led to a small outbreak in Tucson, AZ, in 2008, two hospitals were forced to spend a total of some $800,000 to contain it, much of that related to ensuring the immunity of employees.
-
Having finally wrested a seat at the C-suite table, infection preventionists are now poised to move to the patient bedside. A profession that has labored in relative obscurity for much of its existence is at a critical juncture with a host of influential agents who are suddenly very interested in infection prevention: patients, consumer advocates, state and federal regulators. A path to empowerment has opened.